MYH-9 related platelet disorders: Strategies for management and diagnosis

Transfusion Medicine and Hemotherapy

Volumn 37, Issue 5, 2010, Pages 260-267

  Althaus, Karina ^a   Greinacher, Andreas ^a  

^a UNIVERSITY OF GREIFSWALD   (Germany)

Author keywords

Epstein syndrome; Fechtner syndrome; Macrothrombocytopenia; May Hegglin anomaly; MYH9 gene; Non musclular myosin IIA; Sebastian platelet syndrome

Indexed keywords

AUTOIMMUNE THROMBOCYTOPENIA; BLEEDING; BLOOD SMEAR; CATARACT; CLINICAL FEATURE; DIAGNOSTIC ERROR; FECHTNER SYNDROME; GENE; GENE MUTATION; HEARING LOSS; HUMAN; IMMUNOFLUORESCENCE; IRON DEFICIENCY ANEMIA; KIDNEY FAILURE; MAY HEGGLIN ANOMALY; MENORRHAGIA; MYH 9 GENE; NONHUMAN; REVIEW; SEBASTIAN PLATELET SYNDROME; SKIN BRUISING; THROMBOCYTE DISORDER; THROMBOCYTOPENIA;

EID: 77957838801     PISSN: 16603796     EISSN: None     Source Type: Journal    
DOI: 10.1159/000320335     Document Type: Review

References (39)

1. Hodge T, Cope MJ: A myosin family tree. J Cell Sci 2000;113 Pt 19:3353-3354
2. May R: Leukozyteneinschlüsse. Dtch Arc Klin Med 1909;96:1-6
3. Hegglin R: Gleichzeitige konstituionelle Verände-rungen an Neutrophilen und Thrombozyten. Helv Med Acta 1945;12:439-440
4. Epstein CJ, Sahud MA, Piel CF: Hereditary mac-rothrombocytopathia, nephritis and deafness. Am J Med 1972;52:299-310
5. Peterson LC, Rao KV, Crosson JT, White JG: Fechtner syndrome - a variant of Alport's syndrome with leukocyte inclusions and macrothrom-bocytopenia. Blood 1985;65:397-406
6. Greinacher A, Nieuwenhuis HK, White JG: Sebastian platelet syndrome: a new variant of hereditary macrothrombocytopenia with leukocyte inclusions. Blut 1990;61:282-288
7. Heath KE, Campos-Barros A, Toren A, Rozen-feld-Granot G, et al: Nonmuscle myosin heavy chain IIA mutations define a spectrum of auto-somal dominant macrothrombocytopenias: May-Hegglin anomaly and Fechtner, Sebastian, Epstein, and Alport-like syndromes. Am J Hum Genet 2001;69:1033-1045
8. Kelley MJ, Jawien W, Ortel TL, Korczak JF: Mutation of MYH9, encoding non-muscle myosin heavy chain A, in May-Hegglin anomaly. Nat Genet 2000;26:106-108
9. Kunishima S, Kojima T, Matsushita T, Tanaka T, et al: Mutations in the NMMHC-A gene cause au-tosomal dominant macrothrombocytopenia with leukocyte inclusions (May-Hegglin anomaly/Sebastian syndrome). Blood 2001;97:1147-1149
10. Martignetti JA, Heath KE, Harris J, Bizzaro N, et al: The gene for May-Hegglin anomaly localizes to a <1-Mb region on chromosome 22q12.3-13.1. Am J Hum Genet 2000;66:1449-1454
11. Seri M, Cusano R, Gangarossa S, Caridi G, et al: Mutations in MYH9 result in the May-Hegglin anomaly, and Fechtner and Sebastian syndromes. The May-Heggllin/Fechtner Syndrome Consortium. Nat Genet 2000;26:103-105
12. Toren A, Rozenfeld-Granot G, Rocca B, Epstein CJ, et al: Autosomal-dominant giant platelet syndromes: a hint of the same genetic defect as in Fechtner syndrome owing to a similar genetic linkage to chromosome 22q11-13. Blood 2000;96:3447-3451
13. Hildebrand MS, de Silva MG, Gardner RJ, Rose E, et al: Cochlear implants for DFNA17 deafness. Laryngoscope 2006;116:2211-2215
14. Lalwani AK, Goldstein JA, Kelley MJ, Luxford W, et al: Human nonsyndromic hereditary deafness DFNA17 is due to a mutation in nonmuscle myosin MYH9. Am J Hum Genet 2000;67:1121-1128
15. Behar DM, Rosset S, Tzur S, Selig S, et al: African ancestry allelic variation at the MYH9 gene contributes to increased susceptibility to non-diabetic end-stage kidney disease in Hispanic Americans. Hum Mol Genet 2010;19:1816-1827
16. Marigo V, Nigro A, Pecci A, Montanaro D, et al: Correlation between the clinical phenotype of MYH9-related disease and tissue distribution of class II nonmuscle myosin heavy chains. Genomics 2004;83:1125-1133
17. Simons M, Wang M, McBride OW, Kawamoto S, et al: Human nonmuscle myosin heavy chains are encoded by two genes located on different chromosomes. Circ Res 1991;69:530-539
18. Toothaker LE, Gonzalez DA, Tung N, Lemons RS, et al: Cellular myosin heavy chain in human leukocytes: isolation of 5' cDNA clones, characterization of the protein, chromosomal localization, and upregulation during myeloid differentiation. Blood 1991;78:1826-1833
19. Fox JE, Phillips DR: Role of phosphorylation in mediating the association of myosin with the cytoskeletal structures of human platelets. J Biol Chem 1982;257:4120-4126
20. Kumar CC, Mohan SR, Zavodny PJ, Narula SK, et al: Characterization and differential expression of human vascular smooth muscle myosin light chain 2 isoform in nonmuscle cells. Biochemistry 1989;28:4027-4035
21. Paul BZ, Daniel JL, Kunapuli SP: Platelet shape change is mediated by both calcium-dependent and-independent signaling pathways. Role of p160 Rho-associated coiled-coil-containing protein kinase in platelet shape change. J Biol Chem 1999;274:28293-28300
22. Suzuki Y, Yamamoto M, Wada H, Ito M, et al: Agonist-induced regulation of myosin phosphatase activity in human platelets through activation of Rho-kinase. Blood 1999;93:3408-3417
23. Berg JS, Powell BC, Cheney RE: A millennial my-osin census. Mol Biol Cell 2001;12:780-794
24. Kunishima S, Matsushita T, Kojima T, Sako M, et al: Immunofluorescence analysis of neutrophil non-muscle myosin heavy chain-A in MYH9 disorders: association of subcellular localization with MYH9 mutations. Lab Invest 2003;83:115-122
25. Maupin P, Phillips CL, Adelstein RS, Pollard TD: Differential localization of myosin-II isozymes in human cultured cells and blood cells. J Cell Sci 1994; 107 Pt 11:3077-3090
26. Pecci A, Panza E, Pujol-Moix N, Klersy C, et al: Position of nonmuscle myosin heavy chain IIA (NMMHC-IIA) mutations predicts the natural history of MYH9-related disease. Hum Mutat 2008; 29:409-417
27. Noris P, Klersy C, Zecca M, Arcaini L, et al: Platelet size distinguishes between inherited macro-thrombocytopenias and immune thrombocytope-nia. J Thromb Haemost 2009;7:2131-2136
28. Savoia A, Balduini A: MYH9-related disorders; in Pagon RA, Bird TC, Dolan CR, Stephens K (eds): GeneReviews [Internet]. Seattle: University of Washington, 1993-2008 Nov 20 [updated 2009 Jun 25]
29. Kunishima S, Matsushita T, Kojima T, Amemiya N, et al: Identification of six novel MYH9 mutations and genotype-phenotype relationships in autosomal dominant macrothrombocytopenia with leukocyte inclusions. J Hum Genet 2001;46:722-729
30. Kunishima S, Hamaguchi M, Saito H: Differential expression of wild-type and mutant NMMHC-IIA polypeptides in blood cells suggests cell-specific regulation mechanisms in MYH9 disorders. Blood 2008;111:3015-3023
31. Althaus K, Greinacher A: MYH9-related platelet disorders. Semin Thromb Hemost 2009;35:189-203
32. Eugster M, Reinhart WH: The influence of the haematocrit on primary haemostasis in vitro. Thromb Haemost 2005;94:1213-1218
33. Nakao N, Yoshimura A, Morita H, Takada M, et al: Combination treatment of angiotensin-II receptor blocker and angiotensin-converting-enzyme inhibitor in non-diabetic renal disease (COOPERATE): a randomised controlled trial. Lancet 2003; 361:117-124
34. Pecci A, Granata A, Fiore CE, Balduini CL: Renin-angiotensin system blockade is effective in reducing proteinuria of patients with progressive neph-ropathy caused by MYH9 mutations (Fechtner-Ep-stein syndrome). Nephrol Dial Transplant 2008;23: 2690-2692
35. Sehbai AS, Abraham J, Brown VK: Perioperative management of a patient with May-Hegglin anomaly requiring craniotomy. Am J Hematol 2005;79: 303-308
36. McBane RD, Elliott MA, White JG, Charlesworth JE, Costopoulos MG, Owen WG, Nichols WL: Fechtner syndrome: physiologic analysis of mac- rothrombocytopenia. Blood Coagul Fibrinolysis 2000;11:243-247
37. Heller PG, Pecci A, Glembotsky AC, Savoia A, et al: Unexplained recurrent venous thrombosis in a patient with MYH9-related disease. Platelets 2006;17:274-275
38. Selleng K, Lubenow LE, Greinacher A, Wark-entin TE: Perioperative management of MYH9 hereditary macrothrombocytopenia (Fechtner syndrome). Eur J Haematol 2007;79:263-268
39. Chen Z, Naveiras O, Balduini A, Mammoto A, et al: The May-Hegglin anomaly gene MYH9 is a negative regulator of platelet biogenesis modulated by the Rho-ROCK pathway. Blood 2007;110:171-179